Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group

Hans Erik Johnsen, Tobias W Klausen, Martin Boegsted, Stig Lenhoff, Peter Gimsing, Ilse Christiansen, Tobias Gedde-Dahl, Roald Lindås, Ulf-Henrik Mellqvist, Nordic Myeloma Study Group

    2 Citationer (Scopus)

    Abstract

    An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.
    OriginalsprogEngelsk
    TidsskriftClinical Lymphoma & Myeloma
    Vol/bind10
    Udgave nummer4
    Sider (fra-til)290-6
    Antal sider7
    ISSN1557-9190
    DOI
    StatusUdgivet - 1 aug. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group'. Sammen danner de et unikt fingeraftryk.

    Citationsformater